Positioning of the fixed dose combination of Rosuvastatin + Clopidogrel + Aspirin in the Treatment of Cardiovascular Diseases

Dual anti-platelet therapy (DAPT) and statins are recommended by guidelines for the management of cardiovascular diseases (CVDs), even though the duration of treatment is guided by ischemic and bleeding risk. Clopidogrel and aspirin are the most commonly used DAPT in CVDs. Adding a statin to DAPT is helpful in reducing the thrombosis risk. Fixed-dose combination (FDC) therapy in CVD can help to address the factors of convenience, compliance, control, cost, and complication better than free drug combinations. Therefore, the FDC of rosuvastatin (10 mg or 20 mg) + clopidogrel (75 mg) + aspirin (75 mg) is likely to improve compliance in CVD patients, thereby reducing adverse cardiovascular outcomes and cost of treatment. There is lack of awareness on long term benefits of this FDC in Indian patients.

Refractory vasospasm of the left anterior descending artery causing hemodynamic instability after percutaneous coronary intervention

Refractory coronary vasospastic angina is prone to fatal outcomes. Therefore, it is crucial that the most suitable treatment strategy be promptly elected so as to avert further cardiac complications. Here, authors present the clinical course of profound refractory coronary vasospastic angina in a 50-year-old man. Authors elected to manage the patient through stent implantation. Despite, a complication of perforation followed by refractory coronary vasospasm, authors elected to implant a second stent to relieve the patient from all symptoms.